Cargando…

Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease

Background: National Institute on Aging—Alzheimer's Association (NIA-AA) proposed the AT(N) system based on β-amyloid deposition, pathologic tau, and neurodegeneration, which considered the definition of Alzheimer's disease (AD) as a biological construct. However, the associations between...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Rong-Rong, Xue, Yan-Yan, Li, Xiao-Yan, Chen, Yi-He, Tao, Qing-Qing, Wu, Zhi-Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377373/
https://www.ncbi.nlm.nih.gov/pubmed/34421579
http://dx.doi.org/10.3389/fnagi.2021.718959
_version_ 1783740646086934528
author Lin, Rong-Rong
Xue, Yan-Yan
Li, Xiao-Yan
Chen, Yi-He
Tao, Qing-Qing
Wu, Zhi-Ying
author_facet Lin, Rong-Rong
Xue, Yan-Yan
Li, Xiao-Yan
Chen, Yi-He
Tao, Qing-Qing
Wu, Zhi-Ying
author_sort Lin, Rong-Rong
collection PubMed
description Background: National Institute on Aging—Alzheimer's Association (NIA-AA) proposed the AT(N) system based on β-amyloid deposition, pathologic tau, and neurodegeneration, which considered the definition of Alzheimer's disease (AD) as a biological construct. However, the associations between different AT(N) combinations and cognitive progression have been poorly explored systematically. The aim of this study is to compare different AT(N) combinations using recognized biomarkers within the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Methods: A total of 341 participants were classified into cognitively unimpaired (CU; n = 200) and cognitively impaired (CI; n = 141) groups according to the clinical manifestations and neuropsychological tests. Cerebrospinal fluid (CSF) Aβ42 and amyloid-PET ([18F]flutemetamol) were used as biomarkers for A; CSF phosphorylated tau (p-tau) and tau-PET ([18F]flortaucipir) were used as biomarkers for T; CSF total tau (t-tau), hippocampal volume, temporal cortical thickness, [18F]fluorodeoxyglucose (FDG) PET, and plasma neurofilament light (NfL) were used as biomarkers for (N). Binary biomarkers were obtained from the Youden index and publicly available cutoffs. Prevalence of AT(N) categories was compared between different biomarkers within the group using related independent sample non-parametric test. The relationship between AT(N) combinations and 12-year longitudinal cognition was assessed using linear mixed-effects modeling. Results: Among the CU participants, A–T–(N)– was most common. More T+ were detected using p-tau than tau PET (p < 0.05), and more (N)+ were observed using fluid biomarkers (p < 0.001). A+T+(N)+ was more common in the CI group. Tau PET combined with cortical thickness best predicted cognitive changes in the CI group and MRI predicted changes in the CU group. Conclusions: These findings suggest that optimal AT(N) combinations to determine longitudinal cognition differ by cognitive status. Different biomarkers within a specific component for defining AT(N) cannot be used identically. Furthermore, different strategies for discontinuous biomarkers will be an important area for future studies.
format Online
Article
Text
id pubmed-8377373
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83773732021-08-21 Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease Lin, Rong-Rong Xue, Yan-Yan Li, Xiao-Yan Chen, Yi-He Tao, Qing-Qing Wu, Zhi-Ying Front Aging Neurosci Neuroscience Background: National Institute on Aging—Alzheimer's Association (NIA-AA) proposed the AT(N) system based on β-amyloid deposition, pathologic tau, and neurodegeneration, which considered the definition of Alzheimer's disease (AD) as a biological construct. However, the associations between different AT(N) combinations and cognitive progression have been poorly explored systematically. The aim of this study is to compare different AT(N) combinations using recognized biomarkers within the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Methods: A total of 341 participants were classified into cognitively unimpaired (CU; n = 200) and cognitively impaired (CI; n = 141) groups according to the clinical manifestations and neuropsychological tests. Cerebrospinal fluid (CSF) Aβ42 and amyloid-PET ([18F]flutemetamol) were used as biomarkers for A; CSF phosphorylated tau (p-tau) and tau-PET ([18F]flortaucipir) were used as biomarkers for T; CSF total tau (t-tau), hippocampal volume, temporal cortical thickness, [18F]fluorodeoxyglucose (FDG) PET, and plasma neurofilament light (NfL) were used as biomarkers for (N). Binary biomarkers were obtained from the Youden index and publicly available cutoffs. Prevalence of AT(N) categories was compared between different biomarkers within the group using related independent sample non-parametric test. The relationship between AT(N) combinations and 12-year longitudinal cognition was assessed using linear mixed-effects modeling. Results: Among the CU participants, A–T–(N)– was most common. More T+ were detected using p-tau than tau PET (p < 0.05), and more (N)+ were observed using fluid biomarkers (p < 0.001). A+T+(N)+ was more common in the CI group. Tau PET combined with cortical thickness best predicted cognitive changes in the CI group and MRI predicted changes in the CU group. Conclusions: These findings suggest that optimal AT(N) combinations to determine longitudinal cognition differ by cognitive status. Different biomarkers within a specific component for defining AT(N) cannot be used identically. Furthermore, different strategies for discontinuous biomarkers will be an important area for future studies. Frontiers Media S.A. 2021-08-06 /pmc/articles/PMC8377373/ /pubmed/34421579 http://dx.doi.org/10.3389/fnagi.2021.718959 Text en Copyright © 2021 Lin, Xue, Li, Chen, Tao and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Lin, Rong-Rong
Xue, Yan-Yan
Li, Xiao-Yan
Chen, Yi-He
Tao, Qing-Qing
Wu, Zhi-Ying
Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
title Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
title_full Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
title_fullStr Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
title_full_unstemmed Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
title_short Optimal Combinations of AT(N) Biomarkers to Determine Longitudinal Cognition in the Alzheimer's Disease
title_sort optimal combinations of at(n) biomarkers to determine longitudinal cognition in the alzheimer's disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377373/
https://www.ncbi.nlm.nih.gov/pubmed/34421579
http://dx.doi.org/10.3389/fnagi.2021.718959
work_keys_str_mv AT linrongrong optimalcombinationsofatnbiomarkerstodeterminelongitudinalcognitioninthealzheimersdisease
AT xueyanyan optimalcombinationsofatnbiomarkerstodeterminelongitudinalcognitioninthealzheimersdisease
AT lixiaoyan optimalcombinationsofatnbiomarkerstodeterminelongitudinalcognitioninthealzheimersdisease
AT chenyihe optimalcombinationsofatnbiomarkerstodeterminelongitudinalcognitioninthealzheimersdisease
AT taoqingqing optimalcombinationsofatnbiomarkerstodeterminelongitudinalcognitioninthealzheimersdisease
AT wuzhiying optimalcombinationsofatnbiomarkerstodeterminelongitudinalcognitioninthealzheimersdisease